Antibodies against the NANP central repeat region of CSP have consistently been used as a measure of immunogenicity for the RTS,S/AS01 malaria vaccine as this is the primary target of the vaccine-induced humoral response [7, 23]. This evidence concerns the gene NANP and malaria.